Unknown

Dataset Information

0

Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia.


ABSTRACT: Treatment paradigm of acute promyelocytic leukemia (APL) is by no mean the most remarkable story of cancer therapy. Recently, the advent of oral arsenic formulations (oral-arsenic trioxide and Realgar-Indigo Naturalis formula (RIF)) based regimens may provide a therapeutic advance by curing APL with two oral agents. Indeed, the oral RIF plus all-trans-retinoic acid (ATRA) without chemotherapy display highly efficacy in patients with APL. The safety profile of RIF plus ATRA make possible to treat APL patients in a home-based manner during postremission therapy. To our knowledge, RIF was the first commercially available oral arsenic agent approved in China. The RIF plus ATRA regimens are becoming a preferred frontline care for APL in China. In this review, we will discuss the history, current evidences and challengers of RIF-based strategies in APL. More and more APL patients may enjoy a cure with a normal quality-of-life after induction in the near future.

SUBMITTER: Lou Y 

PROVIDER: S-EPMC7892950 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia.

Lou Yinjun Y   Ma Yafang Y   Jin Jie J   Zhu Honghu H  

Frontiers in oncology 20210205


Treatment paradigm of acute promyelocytic leukemia (APL) is by no mean the most remarkable story of cancer therapy. Recently, the advent of oral arsenic formulations (oral-arsenic trioxide and Realgar-Indigo Naturalis formula (RIF)) based regimens may provide a therapeutic advance by curing APL with two oral agents. Indeed, the oral RIF plus all-trans-retinoic acid (ATRA) without chemotherapy display highly efficacy in patients with APL. The safety profile of RIF plus ATRA make possible to treat  ...[more]

Similar Datasets

| S-EPMC2290784 | biostudies-literature
| S-EPMC6282847 | biostudies-literature
| S-EPMC6941314 | biostudies-literature
| S-EPMC4938459 | biostudies-literature
| S-EPMC6882473 | biostudies-literature
| S-EPMC5967331 | biostudies-literature
| S-EPMC6812572 | biostudies-literature
| S-EPMC4001092 | biostudies-literature
| S-EPMC4814328 | biostudies-literature
| S-EPMC7750395 | biostudies-literature